1
See References in Text note below.
of title 21 a report, in accordance with paragraph (3), that describes the objectives and activities of the program assisted under this section.References in Text
Sections 1501 and 1504 of title 21, referred to in subsec. (c), were repealed by [Pub. L. 100–690, title I, § 1009], Nov. 18, 1988, [102 Stat. 4188].
Amendments
2007—Subsec. (e). [Pub. L. 109–482] struck out heading and text of subsec. (e). Text read as follows: “For the purpose of carrying out this section, there are authorized to be appropriated $85,000,000 for fiscal year 1993, and $95,000,000 for fiscal year 1994.”
1993—Subsec. (b)(6). [Pub. L. 103–43] substituted “Institute” for “Administration”.
Statutory Notes and Related Subsidiaries
Effective Date of 2007 Amendment
Amendment by [Pub. L. 109–482] applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see [section 109 of Pub. L. 109–482], set out as a note under section 281 of this title.
Effective Date
Section effective Oct. 1, 1992, with provision for programs providing financial assistance, see section 801(c), (d) of [Pub. L. 102–321], set out as an Effective Date of 1992 Amendment note under section 236 of this title.
Report by Institute on Medicine
[Pub. L. 102–321, title VII, § 701], July 10, 1992, [106 Stat. 436], directed Secretary of Health and Human Services to enter into a contract with a public or nonprofit private entity to conduct a study concerning (1) role of the private sector in development of anti-addiction medications, including legislative proposals designed to encourage private sector development of such medications, (2) process by which anti-addiction medications receive marketing approval from Food and Drug Administration, including an assessment of feasibility of expediting marketing approval process in a manner consistent with maintaining safety and effectiveness of such medications, (3) with respect to pharmacotherapeutic treatments for drug addiction (A) recommendations with respect to a national strategy for developing such treatments and improvements in such strategy, (B) state of the scientific knowledge concerning such treatments, and (C) assessment of progress toward development of safe, effective pharmacological treatments for drug addiction, and (4) other related information determined appropriate by the authors of the study, and to submit to Congress a report of the results of such study not later than 18 months after July 10, 1992.